Optimi Health prices $15 million offering, lists on NASDAQ

Optimi Health Corp. (NASDAQ: OPTH) announced the pricing of its public offering at $6.25 per share and its uplisting to the Nasdaq Capital Market. The pharmaceutical company is offering 2.4 million common shares, with an option for underwriters to purchase an additional 360,000 shares.

The offering is expected to generate approximately $15 million in gross proceeds before underwriting fees and expenses. Joseph Gunnar & Co., LLC serves as the sole book-running manager for the transaction, which is expected to close on May 21, 2026.

The company plans to use proceeds for scaling production and distribution in current markets, expanding into the United States, and funding sales growth and working capital requirements. Trading on the Nasdaq Capital Market under the symbol "OPTH" began May 20, 2026.

Optimi Health completed a 1-for-30 share consolidation effective May 19, 2026, resulting in approximately 3.2 million shares outstanding before the offering. The consolidation was implemented to meet Nasdaq listing requirements.

The Vancouver-based company manufactures psychedelic drug products including MDMA and psilocybin at Health Canada-licensed facilities in British Columbia. Its products are currently available to patients in Australia through the Authorized Prescriber Scheme and in Canada via the Special Access Program.

The offering was completed through a registration statement filed with the Securities and Exchange Commission, which became effective May 19, 2026. The company also utilized Canada's listed issuer financing exemption for the Canadian portion of the offering.

You May Also Be Interested In

• Forbright completes $142.2 million IPO on Nasdaq
• Atossa Therapeutics closes $4.5 million registered direct offering
• Pop Culture Group prices $8 million direct offering at $0.15 per share